Literature DB >> 7959293

Cervical intraepithelial neoplasia in women infected with the human immunodeficiency virus: outcome after loop electrosurgical excision.

T C Wright1, J Koulos, F Schnoll, J Swanbeck, T V Ellerbrock, M A Chiasson, R M Richart.   

Abstract

Our clinical experience with loop electrosurgical excision as therapy for cervical intraepithelial neoplasia (CIN) in women infected with human immunodeficiency virus is described. Information for this analysis was obtained from a retrospective chart review of all women with biopsy-confirmed CIN treated by loop electrosurgical excision who attended our colposcopy clinic during January 1991 to September 1992. Outcomes in women known to be HIV-seropositive were compared to those in women of unknown HIV serostatus. Patients included in the analysis were followed for at least 6 months or until the documentation of recurrent/persistent CIN, and all had at least one post-treatment colposcopic examination, including endocervical curettage and cervical biopsy of any acetowhite lesions. Recurrent/persistent CIN following loop excision was documented in 56% (19 of 34) HIV-infected women compared with 13% (10 of 80) women of unknown serostatus (OR 8.9, P < 0.001). HIV-infected women had a significantly higher rate of recurrent/persistent CIN than women of unknown serostatus, regardless of grade of CIN. In HIV-infected women, recurrent/persistent CIN following loop excision developed in 20% (1 of 5) with CD4+ T-lymphocyte counts > 500 cells/microliters compared to 61% (11 of 18) with CD4+ counts < or = 500 cells/microliters (P = 0.13). Loop electrosurgical excision has a high failure rate in HIV-infected women, and this failure rate may increase as the level of immunosuppression increases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7959293     DOI: 10.1006/gyno.1994.1286

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  11 in total

1.  Perceptions of barriers and facilitators to cervical cancer screening among low-income, HIV-infected women from an integrated HIV clinic.

Authors:  Faith E Fletcher; Meredith Buchberg; Leslie R Schover; Karen Basen-Engquist; Mirjam-Colette Kempf; Roberto C Arduino; Damon J Vidrine
Journal:  AIDS Care       Date:  2014-03-18

2.  See-and-treat approaches to cervical cancer prevention for HIV-infected women.

Authors:  Carla J Chibwesha; Susan Cu-Uvin
Journal:  Curr HIV/AIDS Rep       Date:  2011-09       Impact factor: 5.071

3.  Outcomes after an excisional procedure for cervical intraepithelial neoplasia in HIV-infected women.

Authors:  Laura L Reimers; Susan Sotardi; David Daniel; Lydia G Chiu; Anne Van Arsdale; Daryl L Wieland; Jason M Leider; Xiaonan Xue; Howard D Strickler; David J Garry; Gary L Goldberg; Mark H Einstein
Journal:  Gynecol Oncol       Date:  2010-10       Impact factor: 5.482

Review 4.  Postmodern cancer: the role of human immunodeficiency virus in uterine cervical cancer.

Authors:  B Clarke; R Chetty
Journal:  Mol Pathol       Date:  2002-02

Review 5.  Gynecologic issues in the HIV-infected woman.

Authors:  Helen E Cejtin
Journal:  Infect Dis Clin North Am       Date:  2008-12       Impact factor: 5.982

Review 6.  Human papillomavirus vaccines: where do they fit in HIV-infected individuals?

Authors:  Cynthia Firnhaber; Timothy Wilkin
Journal:  Curr HIV/AIDS Rep       Date:  2012-09       Impact factor: 5.071

7.  Prevalence of risk factors associated with human papillomavirus infection in women living with HIV. Canadian Women's HIV Study Group.

Authors:  C Hankins; F Coutlée; N Lapointe; P Simard; T Tran; J Samson; L Hum
Journal:  CMAJ       Date:  1999-01-26       Impact factor: 8.262

8.  Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  Lynne M Mofenson; Michael T Brady; Susie P Danner; Kenneth L Dominguez; Rohan Hazra; Edward Handelsman; Peter Havens; Steve Nesheim; Jennifer S Read; Leslie Serchuck; Russell Van Dyke
Journal:  MMWR Recomm Rep       Date:  2009-09-04

9.  Management of cryotherapy-ineligible women in a "screen-and-treat" cervical cancer prevention program targeting HIV-infected women in Zambia: lessons from the field.

Authors:  Krista S Pfaendler; Mulindi H Mwanahamuntu; Vikrant V Sahasrabuddhe; Victor Mudenda; Jeffrey S A Stringer; Groesbeck P Parham
Journal:  Gynecol Oncol       Date:  2008-06-16       Impact factor: 5.482

10.  Cost-effectiveness of human papillomavirus vaccination for prevention of cervical cancer in Taiwan.

Authors:  Pang-Hsiang Liu; Fu-Chang Hu; Ping-Ing Lee; Song-Nan Chow; Chao-Wan Huang; Jung-Der Wang
Journal:  BMC Health Serv Res       Date:  2010-01-11       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.